Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Ritonavir / therapeutic use"'
Autor:
Patrick R. Lawler, Rob Fowler, Edward Litton, Colin McArthur, Katrina Orr, Ryan Zarychanski, Christopher W. Seymour, Richard Beasley, Herman Goossens, Timothy D. Girard, John C. Marshall, Rachael Parke, Marc J. M. Bonten, Susan C. Morpeth, Lennie P. G. Derde, Abi Beane, Steven Y. C. Tong, Alisa Higgins, Asad E. Patanwala, Jane C. Parker, Anna McGlothlin, Menno de Jong, Shay McGuinness, Stephanie K. Montgomery, Alistair Nichol, Frank L. van de Veerdonk, Zahra Bhimani, Christopher M. Horvat, Allen C. Cheng, Manu Shankar-Hari, Anthony C. Gordon, Ewan C. Goligher, Farah Al Beidh, Lise J Estcourt, Kelsey Linstrum, Salim Malakouti, Andrew J King, Michelle A. Detry, Bryan J. McVerry, Francois Lamontagne, Rashan Haniffa, Alexis F. Turgeon, Srinivas Murthy, Cameron Green, Yaseen M. Arabi, Paul R Mouncey, Lolowa Al Swaidan, Eamon Duffy, Lindsay R. Berry, Roger J. Lewis, Scott M. Berry, Kathryn M Rowan, Djillali Annane, Christina Saunders, Meredith Buxton, Mark Fitzgerald, Anne Turner, Elizabeth Lorenzi, Adrian Buzgau, Derek C. Angus, David T. Huang, Charlotte Bradbury, Steven A R Webb, Marlene Santos, Daniel F. McAuley, Thomas Hills, Frank M. Brunkhorst
Publikováno v:
Intensive care medicine
Intensive Care Medicine, 47, 8, pp. 867-886
Investigators, REMAP-CAP & Dark, P 2021, ' Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial. ', Intensive care medicine, vol. 47, no. 8, pp. 867-886 . https://doi.org/10.1007/s00134-021-06448-5
2021, ' Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19 : REMAP-CAP randomized controlled trial ', Intensive Care Medicine, vol. 47, no. 8, pp. 867-886 . https://doi.org/10.1007/s00134-021-06448-5
Intensive care medicine, vol 47, iss 8
Arabi, Y M 2021, ' Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19 : REMAP-CAP randomized controlled trial ', Intensive Care Medicine, vol. 47, no. 8, pp. 867-886 . https://doi.org/10.1007/s00134-021-06448-5
Intensive Care Medicine, 47, 867-886
Intensive care medicine, 47(8), 867-886. Springer Verlag
INTENSIVE CARE MEDICINE
Intensive Care Medicine
Intensive Care Medicine, 47, 8, pp. 867-886
Investigators, REMAP-CAP & Dark, P 2021, ' Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial. ', Intensive care medicine, vol. 47, no. 8, pp. 867-886 . https://doi.org/10.1007/s00134-021-06448-5
2021, ' Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19 : REMAP-CAP randomized controlled trial ', Intensive Care Medicine, vol. 47, no. 8, pp. 867-886 . https://doi.org/10.1007/s00134-021-06448-5
Intensive care medicine, vol 47, iss 8
Arabi, Y M 2021, ' Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19 : REMAP-CAP randomized controlled trial ', Intensive Care Medicine, vol. 47, no. 8, pp. 867-886 . https://doi.org/10.1007/s00134-021-06448-5
Intensive Care Medicine, 47, 867-886
Intensive care medicine, 47(8), 867-886. Springer Verlag
INTENSIVE CARE MEDICINE
Intensive Care Medicine
Purpose To study the efficacy of lopinavir-ritonavir and hydroxychloroquine in critically ill patients with coronavirus disease 2019 (COVID-19). Methods Critically ill adults with COVID-19 were randomized to receive lopinavir-ritonavir, hydroxychloro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f60807238eec20d8d9a1e22139c92fa
https://doi.org/10.1007/s00134-021-06448-5
https://doi.org/10.1007/s00134-021-06448-5
Autor:
Talita Duarte-Salles, Hong Zhu, Li Liu, Edward Burn, Kristin Kostka, Jennifer C E Lane, Paula Casajust, Anthony G. Sena, Martina Recalde, Carlos Areia, William Carter, Lin Zhang, Ying Zhang, Marc A. Suchard, Daniel Prieto-Alhambra, Nigam H. Shah, Christian G. Reich, George Hripcsak, Karishma Shah, Lisa M. Schilling, Michael E. Matheny, Jitendra Jonnagaddala, Dalia Dawoud, Kristine E. Lynch, Fredrik Nyberg, Elena Roel, Waheed Ul Rahman Ahmed, Lana Yin Hui Lai, Mengchun Gong, Patrick B. Ryan, Daniel R. Morales, Seng Chan You, Peter R. Rijnbeek, Heba Alghoul, Jaehyeong Cho, Osaid Alser, Jose D. Posada, Paras P. Mehta, Vignesh Subbian, Thamir M. Alshammari, Albert Prats-Uribe, Asieh Golozar, David Vizcaya
Publikováno v:
The BMJ
Prats-Uribe, A, Sena, A G, Lai, L Y H, Ahmed, W U R, Alghoul, H, Alser, O, Alshammari, T M, Areia, C, Carter, W, Casajust, P, Dawoud, D, Golozar, A, Jonnagaddala, J, Mehta, P P, Gong, M, Morales, D R, Nyberg, F, Posada, J D, Recalde, M, Roel, E, Shah, K, Shah, N H, Schilling, L M, Subbian, V, Vizcaya, D, Zhang, L, Zhang, Y, Zhu, H, Liu, L, Cho, J, Lynch, K E, Matheny, M E, You, S C, Rijnbeek, P R, Hripcsak, G, Lane, J C E, Burn, E, Reich, C, Suchard, M A, Duarte-Salles, T, Kostka, K, Ryan, P B & Prieto-Alhambra, D 2021, ' Use of repurposed and adjuvant drugs in hospital patients with covid-19 : Multinational network cohort study ', The BMJ, vol. 373, n1038 . https://doi.org/10.1136/bmj.n1038
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
The BMJ, 373:n1038. BMJ Publishing Group
BMJ
Prats-Uribe, A, Sena, A G, Lai, L Y H, Ahmed, W U R, Alghoul, H, Alser, O, Alshammari, T M, Areia, C, Carter, W, Casajust, P, Dawoud, D, Golozar, A, Jonnagaddala, J, Mehta, P P, Gong, M, Morales, D R, Nyberg, F, Posada, J D, Recalde, M, Roel, E, Shah, K, Shah, N H, Schilling, L M, Subbian, V, Vizcaya, D, Zhang, L, Zhang, Y, Zhu, H, Liu, L, Cho, J, Lynch, K E, Matheny, M E, You, S C, Rijnbeek, P R, Hripcsak, G, Lane, J C E, Burn, E, Reich, C, Suchard, M A, Duarte-Salles, T, Kostka, K, Ryan, P B & Prieto-Alhambra, D 2021, ' Use of repurposed and adjuvant drugs in hospital patients with covid-19 : Multinational network cohort study ', The BMJ, vol. 373, n1038 . https://doi.org/10.1136/bmj.n1038
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
The BMJ, 373:n1038. BMJ Publishing Group
BMJ
Objective To investigate the use of repurposed and adjuvant drugs in patients admitted to hospital with covid-19 across three continents. Design Multinational network cohort study. Setting Hospital electronic health records from the United States, Sp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::275aaeb389c0d4d2d7da36d9aeea03ce
https://pubmed.ncbi.nlm.nih.gov/34020967
https://pubmed.ncbi.nlm.nih.gov/34020967
Autor:
Lionel Piroth, Bruno Mourvillier, Joy Mootien, François-Xavier Lescure, Emmanuel Faure, S. Gallien, Dominique Costagliola, Jean-Christophe Richard, Noemie Mercier, Florent Wallet, Yazdan Yazdanpanah, Marion Noret, Claire Andrejak, Jean-Philippe Lanoix, Julien Poissy, Johan Courjon, Saad Nseir, François Danion, Violaine Tolsma, Alain Makinson, Odile Launay, Raphaël Clere-Jehl, Bruno Lina, Drifa Belhadi, Valérie Pourcher, Antoine Kimmoun, Karine Lacombe, Juliette Saillard, Maude Bouscambert-Duchamp, Stéphane Jauréguiberry, Charles Burdet, Toni Alfaiate, Olivier Epaulard, Minh Patrick Lê, Gilles Peytavin, Elisabeth Botelho-Nevers, Thérèse Staub, Guillaume Martin-Blondel, Alpha Diallo, Lila Bouadma, Aline Dechanet, François Goehringer, Florence Ader, Nathan Peiffer-Smadja, Jean-Christophe Navellou, Christelle Delmas, Rostane Gaci, Kevin Bouiller, Maya Hites, André Cabié, Jean Reuter, Sylvie Leroy, Axelle Dupont, François Raffi, Amandine Gagneux-Brunon, Jean Reignier, Clément Dubost
Publikováno v:
Clinical Microbiology and Infection
Clinical Microbiology and Infection, Elsevier for the European Society of Clinical Microbiology and Infectious Diseases, 2021, S1198-743X (21), pp.00259-7. ⟨10.1016/j.cmi.2021.05.020⟩
Clinical Microbiology and Infection, Elsevier for the European Society of Clinical Microbiology and Infectious Diseases, 2021, 27 (12), pp.1826-1837. ⟨10.1016/j.cmi.2021.05.020⟩
Clinical Microbiology and Infection, 2021, 27 (12), pp.1826-1837. ⟨10.1016/j.cmi.2021.05.020⟩
Clinical Microbiology and Infection, Elsevier for the European Society of Clinical Microbiology and Infectious Diseases, 2021, S1198-743X (21), pp.00259-7. ⟨10.1016/j.cmi.2021.05.020⟩
Clinical Microbiology and Infection, Elsevier for the European Society of Clinical Microbiology and Infectious Diseases, 2021, 27 (12), pp.1826-1837. ⟨10.1016/j.cmi.2021.05.020⟩
Clinical Microbiology and Infection, 2021, 27 (12), pp.1826-1837. ⟨10.1016/j.cmi.2021.05.020⟩
International audience; Objectives: We evaluated the clinical, virological and safety outcomes of lopinavir/ritonavir, lopinavir/ritonavir-interferon (IFN)-β-1a, hydroxychloroquine or remdesivir in comparison to standard of care (control) in coronav
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4a8dd207add00814d32d637b7eef3ab
https://hal.archives-ouvertes.fr/hal-03364426
https://hal.archives-ouvertes.fr/hal-03364426
Publikováno v:
Trivedi, N, Verma, A & Kumar, D 2020, ' Possible treatment and strategies for COVID-19 : review and assessment ', European review for medical and pharmacological sciences, vol. 24, no. 23, pp. 12593-12608 . https://doi.org/10.26355/eurrev_202012_24057
The coronavirus disease 2019 (COVID-19) is declared as an international emergency in 2020. Its prevalence and fatality rate are rapidly increasing but the medication options are still limited for this perilous disease. The emergent outbreak of COVID-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______3818::67e7992fccea44928baf508273a43c1b
https://www.research.manchester.ac.uk/portal/en/publications/possible-treatment-and-strategies-for-covid19(6314579b-9634-4e58-a745-0862e56f0f85).html
https://www.research.manchester.ac.uk/portal/en/publications/possible-treatment-and-strategies-for-covid19(6314579b-9634-4e58-a745-0862e56f0f85).html
Autor:
Mi Ah Han, Farid Foroutan, Andrés Viteri-García, Gordon H Guyatt, Kimia Honarmand, Francois Lamontagne, Xiaorong Hou, Jessica J Bartoszko, Ariel Izcovich, Bonnie Lam, Arnav Agarwal, Assem M. Khamis, Maryam Ghadimi, Andrea Darzi, John Neary, Britta Tendal, Tari Turner, Srinivas Murthy, Sharhzad Motaghi, Quazi Ibrahim, Bo Fang, Diane Heels-Ansdell, Romina Brignardello-Petersen, Gabriel Rada, Reem A. Mustafa, Robin W.M. Vernooij, Anila Qasim, Maura Marcucci, Tahira Devji, Mark Loeb, Thomas Agoritsas, Signe Flottorp, Long Ge, Liangying Hou, Liang Yao, Bram Rochwerg, Behnam Sadeghirad, Qin Liu, Rachel Couban, Ying Wang, Dena Zeraatkar, Lehana Thabane, Irbaz Bin Riaz, Hector Pardo-Hernandez, Shelley McLeod, Carmen Fang, Elena Kum, Ashwini Sreekanta, Charlotte Switzer, George Tomlinson, Zhikang Ye, Lulu Sheng, Ellen Cusano, Juan Pablo Diaz Martinez, Reed A C Siemieniuk, Per Olav Vandvik, Derek K. Chu, Nigar Sekercioglu
Publikováno v:
BMJ. British Medical Journal
BMJ (Clinical Research Edition), Vol. 370 (2020) P. m2980
BMJ
BMJ (Clinical Research Edition), Vol. 370 (2020) P. m2980
BMJ
Objective To compare the effects of treatments for coronavirus disease 2019 (covid-19). Design Living systematic review and network meta-analysis. Data sources WHO covid-19 database, a comprehensive multilingual source of global covid-19 literature,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c53895ab9884c97e80ea0b03cc99d386
http://hdl.handle.net/11375/26524
http://hdl.handle.net/11375/26524
Autor:
Elena Sumarokova, Gina Gualano, Evgeny Belilovski, Armine Izadifar, Eva Tabernero, Pierre Bachez, Alessandro Torre, Maria Luiza de Souza-Galvão, François-Xavier Blanc, Claire Andrejak, Mathilde Fréchet Jachym, Denise Rossato Silva, Paolo Scarpellini, Margarita Marín Royo, Dina Visca, Ángel Domínguez-Castellano, Teresa Rodrigo, Antoine Froissart, Damien Le Dû, Giovanni Sotgiu, Antonio Spanevello, Pierre-Alexandre Bart, Simon Tiberi, Miguel Zabaleta Murguiondo, Frédéric Schlemmer, Marina Tadolini, Rosella Centis, Matteo Saporiti, Sergey Borisov, Giovanni Battista Migliori, Vania Giacomet, Delia Goletti, Frédéric Rivière, Ilaria Motta, Samir Dourmane, Soazic Grard, José Cardoso-Landivar, José-María García-García, Jesica Mazza-Stalder, Fabrizio Palmieri, Luigi Codecasa, Catherine W.M. Ong, Adrián Sánchez-Montalvá, Lia D'Ambrosio, Jan-Willem C. Alffenaar, Paul A. Tambyah
Publikováno v:
The European Respiratory Journal
article-version (AM) Accepted Manuscript
The European respiratory journal, vol. 56, no. 1
European Respiratory Journal
European Respiratory Journal, European Respiratory Society, 2020, 56 (1), ⟨10.1183/13993003.01398-2020⟩
European Respiratory Journal, 2020, 56 (1), ⟨10.1183/13993003.01398-2020⟩
article-version (AM) Accepted Manuscript
The European respiratory journal, vol. 56, no. 1
European Respiratory Journal
European Respiratory Journal, European Respiratory Society, 2020, 56 (1), ⟨10.1183/13993003.01398-2020⟩
European Respiratory Journal, 2020, 56 (1), ⟨10.1183/13993003.01398-2020⟩
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease (COVID-19) pandemic has attracted interest because of its global rapid spread, clinical severity, high mortality rate, and capacity to overwhelm healthcare systems [1, 2]. SARS-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::afe58fdd4efa3f56b2737cc2d5e084a8
http://hdl.handle.net/11383/2095863
http://hdl.handle.net/11383/2095863
Publikováno v:
International Journal of Molecular Sciences
International Journal of Molecular Sciences, Vol 21, Iss 7768, p 7768 (2020)
International Journal of Molecular Sciences, Vol 21, Iss 7768, p 7768 (2020)
The main challenge in ovarian cancer treatment is the management of recurrences. Facing this scenario, therapy selection is based on multiple factors to define the best treatment sequence. Target therapies, such as bevacizumab and polymerase (PARP) i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ade72d4a51d3f46d9123c2a7191639d
https://hdl.handle.net/10216/145250
https://hdl.handle.net/10216/145250
Autor:
Smit, Mikaela, Marinosci, Annalisa, Nicoletti, Giovanni Jacopo, Perneger, Thomas, Ragozzino, Silvio, Andrey, Diego O, Stoeckle, Marcel, Jacquerioz, Frederique, Lebowitz, Dan, Agoritsas, Thomas, Meyer, Benjamin, Spechbach, Herve, Salamun, Julien, Back, Moritz, Schaubhut, Carla, Fuchs, Simon, Decosterd, Laurent, Battegay, Manuel, Guessous, Idris, Chappuis, François, Kaiser, Laurent, Labhardt, Niklaus D, Calmy, Alexandra
Publikováno v:
BMJ Open, Vol. 10, No 11 (2020) P. e040110
BMJ Open
BMJ Open
IntroductionLopinavir/ritonavir (LPV/r) has been proposed as repurposed drugs for pre-exposure and postexposure prophylaxis as well as therapy of COVID-19. Coronavirus postexposure prophylaxis (COPEP) trial aims at assessing their efficacy as postexp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d4e6b75769eb008996d5f9ae1bb91a4
https://archive-ouverte.unige.ch/unige:155005
https://archive-ouverte.unige.ch/unige:155005
Autor:
Papić, Neven, Dušek, Davorka, Nemeth-Blažić, Tatjana, Kurelac, Ivan, Krznarić, Juraj, Vince, Adriana
Publikováno v:
Liječnički vjesnik
Volume 140
Issue 7-8
Volume 140
Issue 7-8
Sažetak. Kronični hepatitis C (KHC) prepoznat je kao javnozdravstveni problem visokog prioriteta. Svjetska zdravstvena organizacija (SZO) postavila je globalni cilj sniženja smrtnosti za 65% i prevalencije za 90% do 2030. godine. Preduvjet za ostv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______951::bd8a8982837754970ffbc6b882a47d7c
https://hrcak.srce.hr/205703
https://hrcak.srce.hr/205703
Publikováno v:
PharmacoEconomics. 28:147-167
Background: Using data from the phase IIb POWER trials, darunavir boosted with low-dose ritonavir (DRV/r; 600/100 mg twice daily; bid)-based highly active antiretroviral therapy (HAART) was shown to be significantly more efficacious and cost effectiv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed95822aea74d657d697a9ffb9d216ab
https://doi.org/10.2165/11587500-000000000-00000
https://doi.org/10.2165/11587500-000000000-00000